Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition paralleling the growing epidemic of obesity and type-2 diabetes. This disease shows a continuous spectrum of severity ranging from simple steatosis to overt non-alcoholic steato-hepatitis (NASH) that can further progress towards cirrhosis and hepatocarcinoma.1 Although the complete physiopathology is not fully understood, many factors such as insulin resistance, inflammation, oxidative stress and lipotoxicity are involved in the onset of NAFLD.2 ,3 Obstructive sleep apnoea (OSA) is independently associated with the different components of the metabolic syndrome, particularly visceral obesity, hypertension, insulin resistance and abnormal lipid metabolism.4 The repetitive occurrence of partial or complete pharyngeal collapse during OSA induces chronic intermittent hypoxia (CIH) that subsequently results in low-grade inflammation, sympathetic overactivity and oxidative stress. Since OSA and NAFLD share common intermediary mechanisms, the presence of OSA, especially in the context of severe CIH, has been suggested as contributing to the pathogenesis and exacerbation of the severity of NAFLD.
Animal studies have demonstrated that in obesity, short-term or long-term exposure to CIH mimicking OSA induces NAFLD.5–7 Next, studies in human adults, using either non-invasive surrogate markers of liver injury or biopsies to diagnose NAFLD, have also demonstrated that CIH is involved in the development of NAFLD, independently of body mass index (BMI), and contributes to the deleterious progression into overt NASH.8–11 In contrast, other studies have shown that the absence of OSA seems to protect morbidly obese patients from developing NAFLD.12
In response to the currently emergent worldwide epidemic of childhood obesity, NAFLD has started to be more systematically investigated in children than previously.13 ,14 The prevalence of NAFLD reaches 10% in the paediatric population and up to 60% in obese children.15 The literature on paediatric NAFLD is growing in terms of epidemiology, diagnostic procedures and research into the mechanistic pathways.16 A better understanding of the pathophysiology of the disease will help to delineate new treatment strategies, which are currently limited both for adults and even more so for children. Recent studies have demonstrated that OSA is more frequent in children with NAFLD even in non-obese individuals. The dose–response relationship between the amount of oxygen desaturation during the night and the severity of liver injury that has been established in adults also seems to prevail in children.17 ,18
Several factors have been demonstrated as mediating the effects of OSA/CIH on the liver. OSA exacerbates metabolic abnormalities such as insulin resistance and overt type-2 diabetes, independently of BMI.19–21 OSA also plays a role in aggravating dyslipidaemia, which is known to be involved in NAFLD, both in humans22 and in murine models.6 Hepatic lipogenesis, the first stage of NAFLD, is increased by CIH. Indeed, gene expression of lipogenic factors, such as sterol regulatory element-binding proteins-1c and acetyl-CoA carboxylase, is upregulated in murine models of CIH.23 As a result, hepatic triglyceride content is increased by CIH both in lean and obese mice.7 OSA generates oxidative stress throughout the whole body as well as in the liver.6 ,7 The production of reactive oxygen species favours liver lipid peroxydation, which can be prevented by the use of antioxidants.7 ,24 Finally, systemic inflammation is also enhanced OSA patients with NAFLD.8 ,20 Gene expression of the inflammation transcription factor NF-κβ is observed in the liver of patients with NAFLD.25 In children, local liver inflammation has been documented by an increase in intrahepatic leucocytes and activated macrophages/Kupffer cells, particularly in those with the highest levels of nocturnal oxygen desaturation.17
In the current issue of this journal, Nobili et al decipher new mechanistic aspects underlying the link between OSA and NAFLD in children. Using liver biopsies, they studied a large cohort of 81 children who also underwent polysomnography and an assessment of in vivo intestinal permeability. They first confirmed that NAFLD in children is related to OSA severity. Most importantly, they found that OSA increased intestinal permeability resulting in increased systemic levels of lipopolysaccharides (LPS). Interestingly, in the liver, this resulted in an upregulation of toll-like receptors (TLR-4) in hepatocytes, Kupffer cells and hepatic stellate cells (HSC) (figure 1). This family of molecules expressed on cell surfaces detects lipoproteins and lipids from bacteria, protozoa and fungi. LPS are a component of the Gram negative bacterial membrane and bind naturally to LPS-binding protein (LBP) and CD14. LBP is a soluble acute-phase protein primarily produced by hepatocytes in response to microbial translocation. The LPS-LBP-CD14 complex further activates TLR-4 situated on immune cells, adipocytes, hepatocytes and Kupffer cells. These results demonstrate that OSA induces a disruption of the gut–liver axis, increasing susceptibility to endotoxaemia, and suggest that gut microbiota might be one of the culprits of OSA-related NASH. Kheirandish-Gozal et al26 have recently demonstrated, in a large cohort of 219 children, that systemic LPS levels increased along with OSA severity. Importantly, increased LBP serum levels have been associated with cardiovascular risk and mortality.27 This suggests that OSA-related NAFLD may also contribute to the development of cardiovascular disease in children. The role of gut microbiota in NAFLD pathogenesis has been suggested (see for review ref. 28). Bäckhed et al29 demonstrated that the transfer of gut microbiota from diet induced obese mice into axenic mice (ie, mice without microbiota) led to the development of NAFLD. Subsequently, the link between NAFLD, microbiota and intestinal permeability was assessed. A study in rodents elegantly demonstrated that increased intestinal permeability led to elevated endotoxaemia (systemic levels of LPS) and was associated with metabolic alterations such as insulin resistance, glucose intolerance, systemic and tissue inflammation as well as higher liver triglyceride levels.30–32 In contrast, interventions that modify the microbiota, such as antibiotic and prebiotic use, induced a significant improvement in intestinal permeability, metabolic alterations and NAFLD.32 ,33 Importantly, increased intestinal permeability is generally attributed to a high fat diet. In this current issue of Thorax, Nobili et al describe a new finding: the role of OSA/CIH in inducing intestinal permeability. This effect was apparently independent of differences in diet. Indeed, patients with or without NAFLD and with or without OSA displayed similar food intake profiles with regards to the proportion of saturated or unsaturated fat and carbohydrate in their diet as assessed by dietary records. This is in line with results by Moreno-Indias et al who used a mouse model of OSA to demonstrate that intermittent hypoxia exposure translated into distinct hypoxia/reoxygenation patterns in the faeces proximal to the bowel epithelium (<200 μm). This suggests increased intestinal permeability due to altered tight junction integrity. Intermittent hypoxia also altered the composition and diversity of the microbiota potentially leading to downstream metabolic dysregulation.34
Finally, Nobili et al looked deeper into the mechanistic ramifications. They show that OSA might exacerbate NAFLD features by inducing an upregulation of TLR-4 in HSC, thus explaining the increased severity of NAFLD they observed in children with OSA. This is in line with previous studies in mice which had shown that TLR-4 is essential for hepatic fat deposition.35–37 Furthermore, it has been demonstrated that TLR-4 promotes fibrogenesis through activation of the inflammatory cascade in HSC.38 ,39
In summary, the literature provides a number of arguments implicating OSA and particularly CIH in NAFLD pathogenesis and exacerbation in both rodents and humans. Recent findings suggest that this can also occur in children. Nobili et al provide new evidence about the causal role of gut–liver axis disruption and the mechanistic pathway linking OSA and NAFLD, as shown in figure 1. They shed new light on the role of the microbiota in this disease, potentially opening novel therapeutic approaches to NAFLD.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.